АКТУАЛЬНЫЕ ВОПРОСЫ КЛАССИФИКАЦИИ ОЖИРЕНИЯ
https://doi.org/10.15829/1728-8800-2015-4-103-110
Аннотация
Целью настоящего обзора является анализ современных классификаций ожирения, рассматриваемых с точки зрения стратификации риска сердечно-сосудистых (ССЗ) и метаболических заболеваний, оценки влияния на риск осложнений и отдаленный прогноз (смертность). Новая классификация ожирения AACE/ACE (2014) позволяет сконцентрировать внимание и начать многофакторную коррекцию веса именно у лиц с наибольшим риском развития осложнений и ухудшения состояния здоровья. Вместе с тем, в условиях дефицита времени, отведенного врачу первичного звена на осмотр пациента, а также необходимости проведения дополнительных к программе диспансеризации исследований, использование данной классификации проблематично. К настоящему времени не получено убедительных доказательств того, что ИМТ 25-35 кг/м2 без учета метаболических изменений, окружности талии (ОТ), соотношения жира и мышечной ткани является фактором риска (ФР) более высокой сердечно-сосудистой смертности (по сравнению с нормальным ИМТ) в долгосрочной перспективе. В настоящее время существует целый ряд определений метаболически здорового ожирения (МЗО), в которых используются различные критерии оценки здорового метаболизма. Соответственно, будущие исследования должны сосредоточиться на разработке единого определения МЗО и выделения континген- тов, наиболее подверженных высокому риску развития ССЗ и метаболических заболеваний.
Об авторах
И. В. СамородскаяРоссия
д. м.н., профессор, руководитель лаборатории
Е. В. Болотова
Россия
д. м.н., профессор кафедры терапии №1 ФПК и ППС
С. А. Бойцов
Россия
д. м.н., профессор, директор
Список литературы
1. Zheng W, McLerran D, Rolland B, et al. Association between body-massindex and risk of death in more than 1 million Asians. N Engl J Med 2011; 364: 719-29.
2. Frühbeck G, Toplak H, Yumuk EWV, et al. Obesity: The Gateway to ill Health — an EASO Position Statement on a Rising Public Health, Clinical and Scientific Challenge in Europe. Obes Facts 2013; 6(2): 117-120.
3. Jill J. Obesity and the Heart. JAMA 2013; 310(19): 2113.
4. Badkeha A, Rathod A, Kizilbash M, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123(7): 646-51.
5. Carnethon M, De Chavez P, Biggs M, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308(6): 581-90.
6. Ma S, Park B, Yang J, et al. Interaction of body mass index and diabetes as modifiers of cardiovascular mortality in a cohort study. J Prev Med Public 2012; 45(6): 394-401.
7. Kit B, Orpana H, Graubard BI. Association of all-cause mortality with Health. — Overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309(1): 71-82.
8. Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care 2011; 34: 61-5.
9. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14: 219-27.
10. Samocha-Bonet D, Dixit VD, Kahn CR, et al. Metabolically healthy and unhealthy obese: the 2013 Stock Conference report. Obes Rev 2014; 15: 697-708.
11. Seo MH, Rhee EJ. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab 2014; 29(4): 427-34.
12. http://www.who.int/
13. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. JACC 2014; 63(25 Pt B): 2985-3023.
14. Management of Overweight and Obesity Working Group. VA/DoD clinical practice guideline for screening and management of overweight and obesity. Washington (DC): Department of Veterans Affairs, Department of Defense; 2014. p. 178.
15. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne (Australia): National Health and Medical Research Council; 2013. p. 202.
16. Academy of Nutrition and Dietetics. Adult weight management evidence-based nutrition practice guideline. Chicago (IL): Academy of Nutrition and Dietetics; 2014.
17. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015: 100(2); 342-62.
18. De Schutter A, Lavie CJ, Milani RV. The impact of obesity on risk factors and prevalence and prognosis of coronary heart disease-the obesity paradox. Prog Cardiovasc Dis 2014; 56(4): 401-8.
19. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309(1): 71-82.
20. Lavie CJ, Schutter AD, Archer E, et al. Obesity and prognosis in chronic diseases — impact of cardiorespiratory fitness in the obesity paradox. Curr Sports Med Rep 2014; 13(4): 240-5.
21. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56(4): 369-81.
22. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med May 2014; 62: 96-102.
23. Singh P. N., Clark R. W., Herring P. et al. Obesity and Life Expectancy Among LongLived Black Adults. J Gerontol A Biol Sci Med Sci 2014; 69(1): 63-72.
24. Fitch A, Everling L, Fox C, et al. Prevention and management of obesity for adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 May. p. 99.
25. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2012; 33: 1635-701.
26. Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults: Partial Update of CG43. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK); 2014 Nov.
27. World Gastroenterology Organisation (WGO). World Gastroenterology Organisation global guideline: obesity. Milwaukee (WI): World Gastroenterology Organisation 2011.
28. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Futur Cardiol 2005; 1: 39-59.
29. Ruderman NB, Schneider SH, Berchtold P. The “metabolically-obese,” normalweight individual. Am J Clin Nutr 1981; 34: 1617-21.
30. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001; 50: 1499-504.
31. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes 2011; 35: 971-81.
32. Samocha-Bonet D, Chisholm DJ, Tonks K, et al. Insulin-sensitive obesity in humans: a ‘favorable fat’ phenotype? Trends Endocrinol Metab 2012; 23: 116-24.
33. Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013; 1: 152-62.
34. Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 2010; 21: 38-43.
35. Naukkarinen J, Heinonen S, Hakkarainen A, et al. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia 2014; 57: 167-76.
36. Kloting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506-15.
37. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008; 7: 410-20.
38. Koster A, Stenholm S, Alley DE, et al. Health ABC Study. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity 2010; 18: 2354-61.
39. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6(3): 343-68.
40. Badoud F, Perreault M, Zulyniak MA, Mutch DM. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J 2015; 29(3): 748-58.
41. Rice T, Perusse L, Bouchard C, Rao DC. Familial clustering of abdominal visceral fat and total fat mass: the Quebec Family Study. Obes Res 1996; 4: 253-61.
42. Arner P. Regional differences in protein production by human adipose tissue. Biochem Soc Trans 2001; 29(Pt 2): 72-5.
43. Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-37.
44. Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol 2012; 13: 707-12.
45. Navarro E, Funtikova AN, Fito M, Schröder H. Can metabolically healthy obesity be explained by diet, genetics, and inflammation? Mol Nutr Food Res 2015; 59(1): 75-93.
46. Advanced framework for a new diagnosis of obesity as a chronic disease. The American Association of Clinical Endocrinologists and the American College of Endocrinology; 2014.
Рецензия
Для цитирования:
Самородская И.В., Болотова Е.В., Бойцов С.А. АКТУАЛЬНЫЕ ВОПРОСЫ КЛАССИФИКАЦИИ ОЖИРЕНИЯ. Кардиоваскулярная терапия и профилактика. 2015;14(4):103-110. https://doi.org/10.15829/1728-8800-2015-4-103-110
For citation:
Samorodskaya I.V., Bolotova E.V., Boytsov S.A. CURRENT ISSUES OF OBESITY CLASSIFICATION. Cardiovascular Therapy and Prevention. 2015;14(4):103-110. (In Russ.) https://doi.org/10.15829/1728-8800-2015-4-103-110